Although T-DXd is currently indicated for pan-solid tumors with HER2 overexpression (IHC 3+), data from breast cancer studies suggest it may also be effective in tumors with lower HER2 expression levels (IHC 1+ or 0), where AI tools can enhance the consistency and accuracy of HER2 interpretation. The gene discussed is ERBB2; the disease is breast carcinoma.